GlassScriptPhysician profile
Stacie Kubicsko
NPI 1104281633
$4,733.62
in general payments reported to CMS, 2019-2025
48 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $1,659 · 2024: $1,297 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.56 | 2023-2025 | |
| Novo Nordisk INC | $417.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $400.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $358.65 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $355.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $290.22 | 2022-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.38 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $236.82 | 2022-2025 | Rexulti |
| Qol Medical, LLC | $192.03 | 2023-2025 | Sucraid, Sucraid |
| Axsome Therapeutics, INC. | $152.25 | 2022-2025 | Auvelity |
| Shield Therapeutics INC | $127.11 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $109.92 | 2022-2024 | Verquvo, Belsomra, Vaxelis |
| Vanda Pharmaceuticals INC. | $97.19 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.44 | 2023-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $71.70 | 2023-2024 | Clenpiq, Rebyota |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $65.89 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $65.17 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.49 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Lundbeck LLC | $55.92 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $54.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.43 | 2023-2024 | Trintellix |
| Protega Pharmaceutials INC | $49.41 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $48.31 | 2024-2025 | Xtampza, Belbuca |
| Astellas Pharma US INC | $48.06 | 2023-2025 | Veozah, Myrbetriq |
| Vertex Pharmaceuticals Incorporated | $44.80 | 2024-2025 | |
| Mylan Specialty L.P. | $42.36 | 2023-2024 | Yupelri |
| Organon LLC | $40.37 | 2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $38.33 | 2025 | Voquezna |
| Abbott Laboratories | $37.90 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $33.99 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $33.20 | 2023 | Quviviq |
| Exact Sciences Corporation | $31.71 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $29.86 | 2023-2025 | Repatha, Otezla, Prolia |
| Ironwood Pharmaceuticals, INC | $28.13 | 2023 | Linzess |
| Kowa Pharmaceuticals America, INC. | $26.96 | 2022-2023 | Seglentis, Livalo |
| Bioventus LLC | $24.60 | 2025 | Durolane |
| Boston Scientific Corporation | $23.66 | 2023 | Watchman Flx |
| Daiichi Sankyo INC. | $20.94 | 2023 | Injectafer |
| Scilex Pharmaceuticals INC. | $20.52 | 2024 | |
| Agile Therapeutics, INC. | $19.50 | 2023 | Twirla |
| Ardelyx, INC. | $18.48 | 2025 | Ibsrela |
| Saluda Medical Americas, INC. | $18.39 | 2025 | Evoke |
| Sanofi-Aventis U.S. LLC | $18.04 | 2023 | |
| Ibsa Pharma INC. | $17.14 | 2023 | Tirosint, Licart |
| Antares Pharma, INC. | $16.84 | 2024 | Xyosted |
| Corcept Therapeutics | $16.83 | 2023 | Korlym |
| Azurity Pharmaceuticals, INC. | $16.25 | 2025 | Alvesco |
| Tris Pharma INC | $13.97 | 2025 | Onyda Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Kubicsko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.